- DIRECTOR TRANSLATIONAL AND MOLECULAR IMAGING INSTITUTE
- PROFESSOR | Radiology
- PROFESSOR | Medicine, Cardiology
Dr. Fayad serves as professor of Radiology and Medicine (Cardiology) at the Mount Sinai School of Medicine. He is the founding Director of the Translational and Molecular Imaging Institute; Vice chair for Research, Department of Radiology at the Icahn School of Medicine at Mount Sinai. Dr. Fayad’s interdisciplinary and discipline bridging research - from engineering to biology and from pre-clinical to clinical investigations - has been dedicated to the detection and prevention of cardiovascular disease with many seminal contributions in the field of multimodality biomedical imaging (MR, CT, PET and PET/MR) and nanomedicine. His work has recently expanded in understanding the effect of stress on the immune system and cardiovascular disease. He has authored more than 300 peer-reviewed publications (h-index of 71 accessed 01/02/2017 on Thomson Reuters Web of Science), 50 book chapters, and over 500 meeting presentations. He is currently the Principal Investigator (PI) of 5 federal grants (4 R01s and 1 P01) funded by the National Institutes of Health’s National Heart, Lung and Blood Institute and National institute of Biomedical Imaging and Bioengineering. He is also PI on three NIH sub-contracts with UCSD, Columbia and the Brigham and Women’s Hospital. In addition, he serves as Principal Investigator of the Imaging Core of the Mount Sinai National Institute of Health (NIH)/Clinical and Translational Science Awards (CTSA). He is a PI of one of the 3 projects in the Strategically Focused Prevention Research Network Center grant funded by the American Heart Association (AHA) to promote cardiovascular health among high-risk New York City children, and their parents, living in Harlem and the Bronx. Moreover, he currently leads four pharmaceutically funded multicenter clinical trials for the evaluation of novel cardiovascular drugs.
He is Associate Editor for the Journal of the American College of Cardiology Imaging (JACC Imaging), Section Editor for Journal of the American College of Cardiology (JACC) and Consulting Editor for Arteriosclerosis Thrombosis and Vascular Biology (ATVB) and past associate Editor of Magnetic Resonance in Medicine (MRM). In 2013, he became a Charter Member, NIH Center of Scientific Review, Clinical Molecular Imaging and Probe Development Study Section. In 2015, he chaired the Scientific Advisory Board of the Institut National de la Santé et de la Recherche Médicale (INSERM) PARCC program at the HEGP in Paris.
Dr. Fayad had hisengineering trainings at Bradley University (BS, Electrical Engineering ’89), the Johns Hopkins University (MS, Biomedical Engineering ‘91) and at the University of Pennsylvania (PhD. Bioengineering ’96). From 1996 to 1997 he was junior faculty in the Department of Radiology at the University of Pennsylvania. In 1997 he joined the faculty at Mount Sinai School of Medicine.
Dr. Fayad is the recipient of multiple prestigious awards. In 2007 he was given the John Paul II Medal from Krakow, Poland in recognition for the potential of his work on humankind. As a teacher and mentor, Dr. Fayad has been also extremely successful. He has trained over 100 postdoctoral fellows, clinical fellows and students. His trainees have received major awards, fellowships, and positions in academia and industry. In 2008, he received the Outstanding Teacher Award from the International Society of Magnetic Resonance in Medicine (ISMRM) for his teaching on cardiovascular imaging and molecular imaging. In 2009 he was awarded the title of Honorary Professor in Nanomedicine at Aarhus University in Denmark. Recently, he was one of opening speakers at the 2011 97th Scientific Assembly and Scientific meeting of the Radiological Society of North America (RSNA). In 2012, he was invited to give the Henry I Russek Lecture at the 45th Anniversary of the ACCF New York Cardiovascular Symposium. In 2013, he was elected Fellow of the International Society of Magnetic Resonance In Medicine, Magnetic Resonance Imaging, received a Distinguished Reviewer from Magnetic Resonance in Medicine and was selected as an Academy of Radiology Research, Distinguished Investigator In 2014 he received the Centurion Society award from his alma matter (highest award) Bradley University for his bringing national and international credit to his alma matter. In 2014, he received the Editor’s Recognition Award, from the Journal Radiology. In 2015, he was the Dr. Joseph Dvorkin Memorial Lecturer at the Cardiac Research Day of the Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada. In 2015, he became the Mount Sinai Endowed Professor in Medical Imaging and Bioengineering. The Mount Sinai Professorships were established in 2007 by the Mount Sinai Boards of Trustees to honor the achievements and contributions of some of Icahn School of Medicine’s most outstanding faculty. A total of eight Mount Sinai Professorships have been awarded to date in Alzheimer’s Research, Diabetes and Aging, Gene Medicine, Medical Imaging and Bioengineering, Orthopaedics, Orthopaedic Research, Psychiatric Genomics, and Structural Biology. In 2016, he was the Heart & Stroke/Richard Lewar lecturer at the Center of Excellence in Cardiovascular Research in Toronto.
He is married to Monique P. Fayad, MBA and is the proud father of Chloé (15 year old) and Christophe (10 year old) and after spending seven years in Manhattan now lives in Larchmont, runs in Central Park and participates regularly in New York Road Runners races. He also enjoys regular sailing and stand-up board paddling in Larchmont, New York, Connecticut, Rhode Island, Cape Cod, Martha’s Vineyard, Nantucket, the Caribbean Islands and beyond. He also practices all type of daily fitness regimens that include strength, cardiovascular, core, flexibility and high intensity interval trainings for fun.
Atherosclerosis, Cardiovascular, Computed Tomography, Image Analysis, Imaging, Magnetic Resonance Imaging, Nanotechnology
Multi-Disciplinary Training Areas
Biophysics and Systems Pharmacology [BSP], Clinical Research Education Program [CLR]
BSEE, Bradley University
MSE, Johns Hopkins University
PhD, University of Pennsylvania
Opening Session Distinguished Lecturer
Radiological Society of North America
My laboratory is focused on developing and using noninvasive imaging methods that allow the early detection, prevention, and treatment of cardiovascular disease. Despite considerable therapeutic advances over the past 50 years, cardiovascular disease is the leading cause of death worldwide. This is mainly a result of the increasing prevalence of atherosclerosis, owing to the ageing population, the improved survival of patients with atherosclerotic cardiovascular disease and, above all, the widespread under-recognition and undertreatment of individuals with risk factors for atherosclerosis. Atherosclerosis is characterized by the thickening of the arterial wall to form an atherosclerotic plaque, a process in which cholesterol deposition, inflammation, extracellular-matrix formation and thrombosis have important roles (see Sanz and Fayad Nature 2008; 45:953-957). Symptoms occur late in the course of disease and are usually caused by the narrowing of the lumen of the artery, which can happen gradually (as a result of progressive plaque growth) or suddenly (as a result of plaque rupture and, subsequently, thrombosis). The resultant decrease in blood supply can affect almost any organ, although coronary heart disease and stroke are the most common consequences.
Traditionally, diagnosis of atherosclerosis was possible only at advanced stages of disease, either by directly revealing the narrowing of the arterial lumen (stenosis) or by evaluating the effect of arterial stenosis on organ perfusion. We are developing and using, new imaging approaches that allow the assessment not only of the morphology of blood vessels but also of the composition of the vessel walls, enabling atherosclerosis-associated abnormalities in the arteries (including the coronary arteries) to be observed, down to the cellular and molecular level in some cases. Some of these approaches are now in clinical use or are being tested in clinical trials, whereas others are better suited to basic (preclinical) and translational research.
Our current activities are focused on:
Imaging Acquisition and Analysis Methods: Development of novel multimodality cardiovascular imaging and analysis techniques using macro- and micro- Cardiovascular Magnetic Resonance (CMR), computed tomography (CT), positron emission tomography (PET), and optical imaging.
Early Detection and Outcomes Prediction: Use of in vivo noninvasive multimodality imaging methods for the early detection of atherosclerosis in humans and for cardiovascular events and outcomes prediction.
Clinical Trials and Drug Development: Use in vivo noninvasive multimodality imaging methods in clinical trials for the development and testing of novel therapeutics to treat atherosclerosis.
Molecular Imaging: Development and use of novel multimodality imaging nanoparticulate systems to monitor fundamental cellular/molecular events in living subjects including patients.
Drug Delivery: Development and use of novel targeted drug delivery nanoparticulate systems to improve the treatment of atherosclerosis in living subjects including patients.
GEMINI TF PET/MR Clinical Investigation
The purpose of this study is to establish the imaging performance of the new (first in the world) PET/MR (Positron Emission Tomography/Magnetic Resonance) imaging system. The Gemini TF PET/MR provides whole-body PET and MR imaging and is capable of running in combination as...
Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study (CIRT)
Vascular inflammation, a central feature of atherosclerosis, participates in the initiation, perpetuation and instability of plaques. Multiple clinical trials of cholesterol lowering therapy with statins have demonstrated that reductions in atherosclerotic cardiovascular disease ...
A multi-center, randomized, double blind, placebo-controlled, study of the safety, tolerability, and effects on arterial structure and function of ACZ885 (canakinumab) in patients with clinically evident atherosclerosis and either type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT)
The purpose of this study is to look at the safety and effectiveness of an investigational drug called ACZ885 (canakinumab) when used in people with documented Type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT) with atherosclerotic vascular disease . We are inter...
A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients
The purpose of this study is to look at the safety and effectiveness of an investigational drug called BMS-582949 compared to placebo (looks like the study drug but does not have any medicine in it) and atorvastatin (Lipitor™), a lipid-lowering therapy. BMS-582949 is currently be...
Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 2008; 451(7181): 953-957.
Rudd JH, Fayad ZA. Imaging atherosclerotic plaque inflammation. Nature clinical practice 2008; 5(Suppl 2): S11-17.
Mulder WJ, Cormode DP, Hak S, Lobatto ME, Silvera S, Fayad ZA. Multimodality nanotracers for cardiovascular applications. Nature clinical practice 2008; 5 Suppl 2: S103-111.
van Schooneveld MM, Vucic E, Koole R, Zhou Y, Stocks J, Cormode DP, Tang CY, Gordon RE, Nicolay K, Meijerink A, Fayad ZA, Mulder WJ, . Improved Biocompatibility and Pharmacokinetics of Silica Nanoparticles by Means of a Lipid Coating: A Multimodality Investigation. Nano letters 2008;.
Mani V, Adler E, Briley-Saebo KC, Bystrup A, Fuster V, Keller G, Fayad ZA. Serial in vivo positive contrast MRI of iron oxide-labeled embryonic stem cell-derived cardiac precursor cells in a mouse model of myocardial infarction. Magn Reson Med 2008; 60(1): 73-81.
Briley-Saebo KC, Shaw PX, Mulder WJ, Choi SH, Vucic E, Aguinaldo JG, Witztum JL, Fuster V, Tsimikas S, Fayad ZA. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008; 117(25): 3206-3215.
Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, Rafique A, Hargeaves R, Farkouh M, Fuster V, Fayad ZA. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008; 49(6): 871-878.
Calcagno C, Cornily JC, Hyafil F, Rudd JH, Briley-Saebo KC, Mani V, Goldschlager G, Machac J, Fuster V, Fayad ZA. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. Arteriosclerosis, thrombosis, and vascular biology 2008; 28(7): 1311-1317.
Briley-Saebo KC, Mani V, Hyafil F, Cornily JC, Fayad ZA. Fractionated Feridex and positive contrast: in vivo MR imaging of atherosclerosis. Magn Reson Med 2008; 59(4): 721-730.
Lancelot E, Amirbekian V, Brigger I, Raynaud JS, Ballet S, David C, Rousseaux O, Le Greneur S, Port M, Lijnen HR, Bruneval P, Michel JB, Ouimet T, Roques B, Amirbekian S, Hyafil F, Vucic E, Aguinaldo JG, Corot C, Fayad ZA. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arteriosclerosis, thrombosis, and vascular biology 2008; 28(3): 425-432.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Fayad during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Novo Nordisk
Scientific Advisory Board:
- Cerenis Therapeutics
- Daiichi-Sankyo Co., Ltd.
- Isis Pharmaceuticals, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.